Cytokine gene therapy of cancer

Cancer Journal from Scientific American

Volumn 2, Issue 2, 1996, Pages 63-72

  Lotze, Michael T ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL; ARTICLE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; IMMUNOLOGY; METHODOLOGY; NEOPLASM; PHYSIOLOGY;

ANIMALS; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0002569753     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). London: John Bale, Sons & Danielsson, Ltd., 1909.
2. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-410.
3. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol 1995;25:1137-1140.
4. Sobol RE, Scanlon KJ. The Internet Book of Gene Therapy: Cancer Therapeutics. Stamford, Conn: Appleton & Lange, 1995.
5. Dunbar CE, Emmons RVB. Gene transfer into hematopoietic progenitor and stem cells: progress and problems. Stem Cells 1994;12:563-576.
6. Miller AR, McBride WH, Hunt K, Economou JS. Educational reviews: cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1994;1:436-450.
7. Pippin BA, Lotze MT. Cytokine gene therapy of cancer. In Aggarwal BB, Puri RK, eds. Human Cytokines: Their Role in Disease and Therapy; Cambridge: Blackwell Science, 1995:675-688.
8. Lotze MT. Cytokines and the treatment of cancer. Handbook of Experimental Immunology. 5th Ed. in press.
9. Subcommittee on Investigations and Oversight of the Committee on Science and Technology Human Genetic Engineering. Washington: U.S. Government Printing Office, 1983.
10. Kasid A, Morecki S, Aebersold P et al. Human gene transfer: characterization of human tumor infiltrating lymphocytes as vehicles for retrovital mediated gene transfer in man. Proc Natl Acad Sci USA 1990;87:473-477.
11. Culver K, Cornetta K, Motecki S et al. Gene therapy: lymphocytes as cellular vehicles for gene transfer in mouse and man. Proc Natl Acad Sci USA 1992;88:3155-3159.
12. Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-578.
13. Culver KW, Osborne WRA, Miller AD. Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Trans Proc 1991;23:170-175.
14. Bordignon C, Notarangelo D, Nobili N et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA immunodeficient patients. Science 1995;270:470-475.
15. Blaese RM, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for ADA SCID: initial trial results after 4 years. Science 1995;270:475-480.
16. Cai Q, Rubin JT, Lotze MT. Genetically marking human cells - results of the first clinical gene transfer studies. Cancer Gene Ther 1995;2:125-136.
17. Russell SJ. Lymphokine gene therapy for cancer immunol today 1990;11:196-200.
18. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992;339:715-721.
19. Lotze MT, Rubin JT. Interleukin-2. In LeRoith D, Bondy C, eds. Growth factors and cytokines in health and disease. Greenwich, Conn: JAI Press, 1996.
20. Callard R, Gearing A. The cytokine facts book. London: Academic Press, 1994.
21. Thomson A. The Cytokine Handbook. London: Academic Press, 1994.
22. DeVita VT, Hellman S, Rosenberg SA. Biologic Therapy of Cancer. Philadelphia: J. B. Lippincott, 1995.
23. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to herpesvirus saimiri gene. J Immunol 1993;150:5445-56.
24. Lyman SD, James L, Johnson L et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795-801.
25. Muench MO, Roncarolo MG, Menon S et al. FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 1995;85:963-972.
26. Pickup DJ. Poxviral modifiers of cytokine responses to infection. Infect Agents Dis 1994;3:116-27.
27. Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ IL-4 gene expression in cancer patients treated with a genetically-modified tumor vaccine. J Immunother 1995;17:238-248.
28. Bacon KB, Premack BA, Gardner P, Schall TJ. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995;269:1727-1730.
29. Cruikshank WW, Center DM, Nisar N et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci 1994;91:5109-5113.
30. Addison CL, Braciak T, Ralston R et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci 1995;92:8522-8526.
31. Lotze MT. Trials and tribulations: the cost of developing gene therapies [editorial]. FASEB J 1991;5:3013-3014.
32. Bubenik J, Indorva M. Cancer immunotherapy using local interleukin-2 administration. Immunol Lett 1987;16:305-310.
33. Bubenik J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 1990;23:287-292.
34. Russell SJ, Flemming C, Eccles SA, Johnson C, Collins MKL. Transfer and expression of the human IL-2 gene in a transplantable rat sarcoma. In: Lotze MT, Finn OJ, eds. Cellular Immunity and the Immunotherapy of Cancer. New York: Wiley-Liss, 1990;275-278.
35. Fearon ER, Pardoll DM, Itaya T et al. IL-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:297-403.
36. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-1224.
37. Oliff A, Defeo-Jones D, Boyer M et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-563.
38. Blankenstein T, Qin Z, Uberla K et al. Tumor suppression after tumor cell-targeted tumor necrosis factor a gene transfer. J Exp Med 1991;173:1047-1052.
39. Johnson RA, Boyce BF, Mundy GR, Roodman GD. Tumors producing human tumor necrosis factot induce hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinol 1989;124:1424-1427.
40. Asher AL, Mule JJ, Kasid A et al. Murine tumor cells transduced with the gene for TNF-a: evidence for paracrine immune effects of TNF against tumors. J Immunol 1991;146:3227-3234.
41. Teng MN, Park BH, Koeppen HKW, Tracey KJ, Fendly BM, Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 1991;88:3535-3539.
42. Malik STA, Naylor MS, East N, Oliff A, Balkiwill FR. Cells secreting TNF show enhanced metastasis in nude mice. Eur J Cancer 1990;26:1031-1034.
43. Zheng L, Fisher G, Miller RD, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T-cells by tumor necrosis factor. Nature 1995;377:348-351.
44. Marincola RM, Karp SE, Mule JJ, Rosenberg SA. Injection of murine sarcoma cells engineered to secrete human TNF-alpha causes regression of established pulmonary metastases. Proc Am Assoc Cancer Res, 1992;33:350.
45. Miyatake SI, Nishihara K, Kikuchi H et al. Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with IFN-γ gene. J Natl Cancer Inst 1990;82:217-220.
46. Watanabe Y, Kuribayashi K, Miyatake S et al. Exogenous expression of mouse interferon-gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumotigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:9456-9460.
47. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated g-IFN gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-7825.
48. Restifo NP, Esquivel F, Asher AL et al. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J Immunol 1991;147:1453-1459.
49. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175: 1423-1431.
50. Colombo MP, Ferrari G, Stoppacciaro S et al. Granulocyte CSF gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-897.
51. + T cell-dependent tumor rejection. J Exp Med 1991;174:1291-1298.
52. Allione A, Consalvo M, Nanni P et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6026.
53. Torre-Amione G, Beauchamp D, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with a murine TGF type b, cDNA ecapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486-1490.
54. Suzuki T, Tahara H, Robbins P, Narula S, Moore K, Lotze MT. The human herpes virus 4 cIL-10 homologue, vIL-10 induces local anergy to tumor allo and autografts. J Exp Med 1995;182:477-486.
55. Tahara H, Mueller GM, Ricordi C, Robbins PD, Lotze MT. Islet cell transplantation facilitated by gene transfer. Transplant Proc 1992;24:2975-2976.
56. Chavin KD, Qin L, Tahara H, Robbins PD, Lotze MT, Bromberg JS. Gene transfer of TGF-b and viral IL-10 prolong cardiac allograft survival. Surg Forum 1993;44:404-409.
57. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to screte interleukin-4. Science 1991:254:713-716.
58. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-512.
59. Blankenstein T, Li W, Muller W, Diamantstein T. Retroviral interleukin 4 gene transfer into an IL-4-dependent cell line results in autocrine growth but not in tumorigenicity. Eur J Immunol 1990;20:935-938.
60. Li W, Diamantstein T, Blankenstein T. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the antitumor function of interleukin 4. Mol Immunol 1990;27:1331-1337.
61. Bosco M, Giovarelli M, Forni M et al. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990;145:3136-3143.
62. Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Ther 1994;1:1-7.
63. Hunt JD, Pippin AB, Landreneau RJ, Jacob WF, Lotze MT, Siegfried JM. Transfer and expression of the human Interleukin-4 gene in carcinoma and stromal cell strains derived from lung cancer patients. J Immunother 1993;14:314-21.
64. Lotze MT, Rubin JT. Gene Therapy of Cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human Gene Ther 1994;5:41-56.
65. Cascinelli N, Foa R, Parmiani G. Active immunization of metastatic melanoma patients with IL-4 transduced, allogeneic melanoma cells. A phase I/II study. Human Gene Ther 1994;5:1059-1064.
66. Elder EM, Lotze MT, Whiteside TL. Methods for generation of genetically-modified fibroblasts for immunotherapy of cancer. In Robbins P, ed. Methods in Molecular Biology: Gene Therapy Protocols, in press.
67. Fakhrai H, Shawler DL, Gjerset R et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Human Gene Ther 1995;6:591-601.
68. Schmidt-Wolf IG, Huhn D, Neubauer A, Wittig B. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Human Gene Ther 1994;5:1161-1168.
69. Richter G, Kruger-Krasagakes S, Hein G et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993;53,4134-4137.
70. Giovarelli M, Musiani P, Modesti A et al. The local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody dependent immune memory. J Immunol 1995;155:3112-3123.
71. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sci 1993;90:3539-3543.
72. Rosenthal FM, Fruh R, Henschler R et al. Cytokine therapy with gene-transfected cells: single injection of irradiated granulocyte-macrophage colony-stimulating factor-transduced cells accelerates hematopoietic recovery after cytotoxic chemotherapy in mice. Blood 1994;84:2960-2965.
73. Sanda MG, Ayyagari SR, Jaffee EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:622-628.
74. Berns AJ, Clift S, Cohen LK et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF transduction in patients with metastaric renal cell carcinoma. Human Gene Ther 1995;6:347-368.
75. Tahara H, Zeh H, Storkus WJ et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth in vivo and induce antitumor immunity to a murine melanoma. Cancer Res 1994;54:182-189.
76. Tahara H, Zitvogel L, Storkus WJ et al. Effective eradication of established murine tumors with therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-6474.
77. Zitvogel L, Tahara H, Robbins PD et al. Cancer immunotherapy of established tumors with Interleukin-12 (IL-12): effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-1403.
78. Tahara H, Lotze MT. Antitumor effect of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995;2:96-106.
79. Zitvogel L, Tahara H, Robbins PD, Davis G, Lotze MT. Cancer gene therapy using a cytokine IL-12 and a costimulatory molecule B7.1. Proc Am Soc Clin Oncol 1995;14:226.
80. Zitvogel L, Robbins PF, Clarke MR, Abe R, Davis CG, Lotze MT. B7.1 costimulation markedly enhances IL-12 mediated antitumor immunity in vivo. Eur J Immunol 1996; in press.
81. Pappo I, Tahara H, Nishihara K et al. Administration of systemic or local interleukin-2 enhances the antitumor effects of interleukin-12 gene therapy. J Surg Res 1995;57:218-226.
82. Zitvogel L, Tahara H, Robbins PD et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin 12 (IL-12). Human Gene Ther 1994;5:1493.
83. Zitvogel L, Lotze MT. Role of interleukin-12 (IL-12) as an antitumor agent: Experimental biology and clinical application, in press.
84. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. Clinical Protocol: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Human Gene Ther 1995;6: 1607-1624.
85. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251.
86. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J Exp Med 1995;182:283-288.
87. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatability complex class II compartment: downregularion by cytokines and bacterial products. J Exp Med 1995;182:389-400.
88. Zier KS, Gansbacher B. The impact of gene therapy on T cell function in cancer. Human Gene Ther 1995;10:1259-1264.
89. Salvadori S, Bansbacher B, Wernick I, Tirelli S, Zier K. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo but fails to induce a response by naive cells in vitro. Human Gene Ther 1995;10:1299-1306.
90. Wu L, Vremec D, Ardavin C et al. Mouse thymus dendritic cells: kinetics of development and changes in surface markers during maturation. Eur J Immunol 1995;25:418-425.
91. Winkel K, Sotzik F, Vremec D, Cameron PL, Shortman K. CD4 and CD8 expression by human and mouse thymic dendritic cells. Immunol Letters 1994;40:93-99.
92. Young JW, Szabolcs P, Moore MAS. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/ macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 1995;182:1111-1120.
93. Weissman D, Li Y, Orenstein JM, Fauci AS. Both a precursor and a mature population of dendritic cells can bind HIV; however, only the mature population that expresses CD80 can pass infection to unstimulated CD4+ T cells. J Immunol 1995;155:4111-4117.
94. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995;3:459-473.
95. Alijagic S, Möller P, Artuc M, Jurgovsky K, Czarnetzki BM, Schadendorf D. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 1995;25:3100-3107.
96. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with tumor peptides effectively treat established murine tumors. Nature Med 1996; in press.
97. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J Exp Med 1996; in press.
98. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Dendritic cells pulsed with tumor-derived peptides elicit therapeutic immunity against established tumors. J Exp Med 1996; in press.
99. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with dendritic cells pulsed with p53 wild type and mutant sequence peptides. Submitted for publication.
100. Maeurer MJ, Martin DM, Storkus WJ, Lotze MT. Evidence for shared T-cell receptor usage in cytolytic T-cells recognizing HLA-A2 presented antigens shared by melanoma and melanocytes. Immunol Today 1996; in press.
101. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. Immunization with melanoma derived peptide T-cell epitopes represents a new treatment option for patients with melanoma. Melanoma Res 1996; in press.
102. Wang H, O'Malley BW Jr, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994;91:8180-8184.
103. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Nat Acad Sci USA 1993;90:4455-4459.
104. Burkholder JK, Decker J, Yang NS. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J Immunol Methods 1993;165:149-156.
105. Woffendin C, Yang ZY, Udaykumar AM et al. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T-cells. Proc Nat Acad Sci USA 1994;91:11581-5.
106. Sun WH, Burkholder JK, Sun J et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Nat Acad Sci USA 1995;92:2889-93.
107. Feigner PI, Tasai YJ, Sukhu L, Wheeler CJ, Manthorpe M. Improved cationic lipid formulations for in vivo gene therapy. Proc New York Acad Sci 1996; in press.
108. Becker, Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993;7:187.
109. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993;25:338.
110. Furihata M, Ohtsuki Y, Ido E et al., HLA-DR antigen-and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma - their distribution in relation to prognosis. Virchows Archiv B 1992;61:409.
111. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. Infiltration of dendritic cells in relationship to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990;66:2012.
112. Giannini A, Bianchi S, Messerini L et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991;187:496.
113. Knight SC, Hunt R, Dore C, Medawar PB. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985;82:4495-4497.
114. Romani M, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
115. Tan J, Deleuran B, Gesser B et al. Regulation of human T lymphocyte chemotaxis in vitro by T cell-derived cytokines IL-2, IFN-gamma, IL-4, IL-10, and IL-13. J Immunol 1995;154:3742-3752.
116. Hurford RK, Dranoff G, Mulligan RC, Tepper TI. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genetics 1995;10:430-435.
117. Gordon NH, Willson JK. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat Med 1992;11:2063-2075.
118. Melink TJ, Clark GM, Von Hoff DD. The impact of phase I clinical trials on the quality of life of patients with cancer. Anti-Cancer Drugs 1992;3:571-576.
119. Mick R, Ratain MG. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst 1993;85:217-223.
120. Oliver IN. Antiemetic study design: desirable objectives, stratifications and analyses. Br J Cancer 1992;19:S30-S33.